Diabetes mellitus pharmacology in detailed all drug and classification

Reading File

Finding Sources

Reading File

I now have comprehensive content from both Lippincott and Katzung pharmacology textbooks. Let me compile the complete, detailed answer.

Diabetes Mellitus Pharmacology: Complete Drug Classification

Sources: Lippincott Illustrated Reviews Pharmacology (9781975170561); Katzung's Basic and Clinical Pharmacology 16e (9781260463309)

Overview of Diabetes Types

Feature	Type 1 DM	Type 2 DM
Pathophysiology	Absolute insulin deficiency (autoimmune β-cell destruction)	Insulin resistance + progressive β-cell insufficiency
Treatment	Insulin (mandatory)	Lifestyle, oral agents, injectables, insulin as disease progresses
Goal	A1C ≤7% (154 mg/dL mean glucose)	A1C ≤7%, prevent cardiovascular/renal complications

Complete Drug Classification

CLASS 1: INSULIN

Mechanism: Binds insulin receptor (tyrosine kinase) → facilitates glucose uptake into muscle/fat via GLUT-4, inhibits hepatic gluconeogenesis, promotes glycogen synthesis, lipogenesis, and protein synthesis.

Physiology of secretion: Blood glucose → uptake via GLUT into β-cell → glucokinase phosphorylates glucose → ATP rises → K⁺ channel block → membrane depolarization → Ca²⁺ influx → pulsatile insulin exocytosis.

Route: Subcutaneous injection (standard); IV (emergency hyperglycemia); inhaled (Afrezza); insulin pump (CSII - continuous subcutaneous insulin infusion).

A. Rapid-Acting Insulin Analogs

Drug	Brand	Onset	Peak	Duration	Notes
Insulin lispro	Humalog, Lyumjev, Admelog	15 min	1-1.5 h	3-4 h	Lys-Pro swap at B28-B29; U100 and U200
Insulin aspart	Novolog, Fiasp	10-20 min	1-3 h	3-5 h	Pro→Asp at B28; Fiasp is faster-acting
Insulin glulisine	Apidra	15 min	1 h	3-4 h	Lys→Glu at B3, Asn→Lys at B29

Key point: Amino acid substitutions disrupt dimer/hexamer formation → faster subcutaneous absorption. Given just before meals (mealtime bolus).

B. Short-Acting (Regular) Insulin

Drug	Brand	Onset	Peak	Duration
Regular human insulin	Humulin R, Novolin R	30-60 min	2-4 h	6-10 h
Regular insulin inhaled	Afrezza	12-15 min	~1 h	2-3 h

Note: Regular insulin must be given 30-60 min before meals. U500 concentration available for insulin-resistant patients. Used IV in hyperglycemic emergencies (DKA, HHS).

C. Intermediate-Acting Insulin

Drug	Brand	Onset	Peak	Duration
NPH insulin (Neutral Protamine Hagedorn)	Humulin N, Novolin N	1-2 h	4-8 h	12-18 h

Note: Cloudy suspension. Given twice daily. Used for basal glycemic control.

D. Long-Acting Insulin Analogs (Basal Insulins)

Drug	Brand	Onset	Peak	Duration
Insulin glargine	Lantus, Toujeo (U300), Basaglar, Semglee	1-2 h	Peakless	~24 h
Insulin detemir	Levemir	1-2 h	Relatively flat	Up to 24 h
Insulin degludec	Tresiba	1 h	Peakless	>42 h

Mechanism of prolonged action:

Glargine: altered pH → precipitates at injection site, slowly dissolves. Cannot mix with other insulins.
Detemir: fatty acid chain → albumin binding → prolonged release.
Degludec: forms multi-hexamer depot → ultra-long action, very low day-to-day variability.

E. Premixed Insulins

Preparation	Content
70/30 (NPH/Regular)	70% NPH + 30% Regular
75/25 (NPL/Lispro)	Humalog Mix 75/25
50/50 (NPL/Lispro)	Humalog Mix 50/50
70/30 (NPA/Aspart)	Novolog Mix 70/30
70/30 (Degludec/Aspart)	Ryzodeg

F. Insulin Adverse Effects

Effect	Details
Hypoglycemia	Most serious; more frequent with intensive regimens
Weight gain	Anabolic effect
Lipodystrophy	Lipoatrophy or lipohypertrophy at injection sites
Hypokalemia	Insulin drives K⁺ intracellularly
Insulin allergy	Rare with human insulin

Intensive vs. Standard Therapy: Intensive therapy (3+ injections/day, A1C ≤7%) significantly reduces microvascular complications (retinopathy, nephropathy, neuropathy) but increases hypoglycemic episodes. Not recommended for elderly, longstanding DM, hypoglycemia unawareness, or advanced microvascular disease.

CLASS 2: BIGUANIDES

Drug: Metformin (only clinically used biguanide; phenformin withdrawn due to lactic acidosis)

Mechanism:

Primary: Inhibits hepatic gluconeogenesis (decreases hepatic glucose output)
Activates AMP-activated protein kinase (AMPK) → reduces fatty acid synthesis
Mild increase in peripheral insulin sensitivity (GLUT-4 translocation)
Stimulates intestinal GLP-1 secretion
Does NOT stimulate insulin secretion → no hypoglycemia as monotherapy

Pharmacokinetics: Not protein-bound; not metabolized; excreted unchanged by kidneys (tubular secretion and glomerular filtration).

Indications: First-line for Type 2 DM (ADA-recommended); also used in PCOS, prevention of Type 2 DM in high-risk patients.

Adverse effects:

GI: nausea, diarrhea, abdominal discomfort (most common, minimize with meals, slow titration)
Lactic acidosis (rare but serious; more risk in renal failure, hepatic failure, alcoholism, IV contrast)
Vitamin B12 deficiency (long-term use)
Metallic taste

Contraindications:

eGFR <30 mL/min (absolute); caution if eGFR 30-45
Acute heart failure, sepsis, acute illness with hemodynamic instability
Hold 48 h before/after IV contrast dye
Hepatic failure, alcohol abuse

Advantages: Low cost, weight neutral or modest weight loss, no hypoglycemia alone, cardiovascular benefit (UKPDS).

CLASS 3: SULFONYLUREAS

Mechanism: Bind to sulfonylurea receptor (SUR-1) on pancreatic β-cells → close ATP-sensitive K⁺ channels → membrane depolarization → Ca²⁺ influx → insulin exocytosis. Require functioning β-cells.

Key point: Stimulate insulin secretion regardless of blood glucose level → hypoglycemia risk.

First-Generation (largely obsolete):

Tolbutamide, chlorpropamide, tolazamide, acetohexamide

Second-Generation (clinically used):

Drug	Brand	Duration	Notes
Glipizide	Glucotrol, Glucotrol XL	12-24 h	Short-acting; preferred in elderly; hepatically metabolized
Glyburide (glibenclamide)	Micronase, DiaBeta	16-24 h	Also binds cardiac/vascular SUR → avoid in CAD; not preferred in elderly
Glimepiride	Amaryl	24 h	Once daily; least hypoglycemia; some insulin-sensitizing effect

Adverse effects:

Hypoglycemia (most significant - especially glyburide)
Weight gain
Disulfiram-like reaction (chlorpropamide - 1st gen)
Hyponatremia/SIADH (chlorpropamide)
Glyburide unique: sequesters in β-cell → prolonged hypoglycemia

Contraindications: Type 1 DM, pregnancy, severe renal/hepatic disease.

CLASS 4: MEGLITINIDES (Non-Sulfonylurea Insulin Secretagogues)

Mechanism: Same as sulfonylureas - bind SUR-1 on β-cells → K⁺ channel closure → insulin release. But different binding site; shorter duration → target postprandial glucose.

Drug	Brand	Duration	Dosing
Repaglinide	Prandin	1-3 h	Before each meal (2-4x/day); avoid if skipping meals
Nateglinide	Starlix	<2 h	Fastest-acting; most selective for postprandial glucose

Advantages over sulfonylureas: Shorter action → less hypoglycemia risk; more flexible dosing (take only with meals).

Adverse effects: Hypoglycemia (less than sulfonylureas), weight gain.

CLASS 5: THIAZOLIDINEDIONES (TZDs) - "Glitazones"

Mechanism: Bind and activate PPAR-γ (peroxisome proliferator-activated receptor gamma) - nuclear receptor → alter gene transcription → increase insulin sensitivity in muscle, adipose tissue, liver. Do NOT stimulate insulin secretion. Require weeks for full effect.

Drug	Brand	Notes
Pioglitazone	Actos	Preferred; may reduce cardiovascular events (PROactive trial); PPAR-α partial agonist
Rosiglitazone	Avandia	Restricted - FDA black box for MI risk; PPAR-γ only
Troglitazone	Rezulin	Withdrawn - fatal hepatotoxicity

Adverse effects:

Fluid retention/edema (increase renal sodium reabsorption)
Weight gain (fluid + fat redistribution)
Heart failure exacerbation (contraindicated in Class III-IV HF)
Osteoporosis/fractures (inhibit osteoblast differentiation) - especially in women
Bladder cancer risk (pioglitazone - controversial; FDA added warning)
Macular edema

Benefits: Durable glycemic control, reduce triglycerides, increase HDL (pioglitazone).

CLASS 6: DPP-4 INHIBITORS ("Gliptins")

Mechanism: Inhibit dipeptidyl peptidase-4 (DPP-4) enzyme → prevent rapid degradation of endogenous GLP-1 and GIP → prolong incretin action → glucose-dependent insulin secretion + glucagon suppression.

Key advantage: Glucose-dependent → very low hypoglycemia risk. Weight neutral.

Drug	Brand	Dosing
Sitagliptin	Januvia	Once daily; dose-adjust in renal impairment
Linagliptin	Tradjenta	Once daily; no renal dose-adjustment (biliary excretion)
Alogliptin	Nesina	Once daily
Saxagliptin	Onglyza	Once daily; concern for heart failure hospitalization (SAVOR-TIMI)
Vildagliptin	Galvus	Available in Europe; twice daily

Adverse effects:

Nasopharyngitis, upper respiratory infections
Urinary tract infections
Rare: pancreatitis, joint pain
Saxagliptin/alogliptin: possible increased heart failure hospitalization

Contraindications: History of pancreatitis (relative), Type 1 DM.

CLASS 7: GLP-1 RECEPTOR AGONISTS ("Incretins")

Mechanism: Mimic native GLP-1 → activate GLP-1 receptors → glucose-dependent insulin secretion, glucagon suppression, delayed gastric emptying (reduces postprandial glucose), central satiety effects → weight loss. Resistant to DPP-4 degradation (modified structure).

Incretin effect background: Oral glucose causes 60-70% of postprandial insulin release via incretins (GLP-1, GIP). This is markedly reduced in Type 2 DM.

Drug	Brand	Route/Frequency	CV Benefit
Exenatide	Byetta	SC, twice daily	No
Exenatide XR	Bydureon	SC, once weekly	No
Liraglutide	Victoza	SC, once daily	Yes (LEADER trial)
Dulaglutide	Trulicity	SC, once weekly	Yes (REWIND trial)
Semaglutide	Ozempic (SC), Rybelsus (oral)	SC weekly or oral daily	Yes (SUSTAIN-6)
Lixisenatide	Adlyxin	SC, once daily	Neutral
Tirzepatide	Mounjaro	SC, once weekly	GLP-1 + GIP dual agonist

Cardiovascular benefits: Liraglutide, dulaglutide, and semaglutide approved to reduce cardiovascular mortality in Type 2 DM with established CVD.

Adverse effects:

Nausea, vomiting, diarrhea (most common; often transient)
Pancreatitis (rare but serious)
Thyroid C-cell tumors (rodents - black box warning; contraindicated in personal/family history of medullary thyroid carcinoma or MEN2)
Injection site reactions
Weight loss (beneficial)

Contraindications: MEN2, medullary thyroid carcinoma, history of pancreatitis, pregnancy.

Premixed combinations: Insulin glargine + lixisenatide (Soliqua); insulin degludec + liraglutide (Xultophy).

CLASS 8: SGLT-2 INHIBITORS ("Gliflozins")

Mechanism: Inhibit sodium-glucose cotransporter-2 (SGLT-2) in the proximal renal tubule → prevent glucose reabsorption → urinary glucose excretion (glucosuria) → reduces blood glucose independent of insulin.

SGLT-2 handles ~90% of filtered glucose reabsorption in the kidney.

Drug	Brand	Notable Benefits
Empagliflozin	Jardiance	CV mortality reduction (EMPA-REG); heart failure, CKD benefit
Canagliflozin	Invokana	CV events reduction (CANVAS); CKD progression reduction
Dapagliflozin	Farxiga/Forxiga	Heart failure, CKD benefit (DAPA-HF); approved for HFrEF even without DM
Ertugliflozin	Steglatro	CV neutral

Adverse effects:

Genital mycotic infections (most common - due to glucosuria)
UTI
Euglycemic DKA (especially in Type 1 DM or fasting states - rare but serious)
Increased urination/dehydration/hypotension
Canagliflozin: lower limb amputations (black box warning), fractures
Fournier's gangrene (rare, necrotizing fasciitis of perineum)

Contraindications: eGFR <30 (for glycemic efficacy; some still used for HF/CKD protection at lower eGFR with adjusted thresholds), recurrent UTIs/fungal infections, Type 1 DM (relative).

Key benefits: Weight loss (~2-3 kg), blood pressure reduction, heart failure protection, renal protection - independent of glycemic effect.

CLASS 9: ALPHA-GLUCOSIDASE INHIBITORS

Mechanism: Competitively inhibit alpha-glucosidase enzymes in the intestinal brush border → delay digestion and absorption of complex carbohydrates → reduce postprandial glucose spikes. No effect on fasting glucose.

Drug	Brand
Acarbose	Precose
Miglitol	Glyset

Adverse effects:

Flatulence, bloating, diarrhea, abdominal cramps (very common; limits use)
No hypoglycemia when used as monotherapy
If hypoglycemia occurs with combination therapy, must treat with glucose (not sucrose - sucrose absorption is inhibited)

Contraindications: Inflammatory bowel disease, gastroparesis, cirrhosis.

CLASS 10: AMYLIN ANALOG

Drug: Pramlintide (Symlin)

Mechanism: Synthetic analog of amylin (co-secreted with insulin from β-cells) → delays gastric emptying, suppresses postprandial glucagon, promotes satiety.

Indications: Adjunct to mealtime insulin in Type 1 AND Type 2 DM.

Administration: Subcutaneous injection immediately before meals. When initiated, reduce mealtime insulin by 50% to prevent hypoglycemia. Cannot be mixed in same syringe as insulin.

Adverse effects: Nausea, vomiting, anorexia, severe hypoglycemia (when combined with insulin).

Contraindications: Diabetic gastroparesis, hypoglycemia unawareness, cresol hypersensitivity.

CLASS 11: DOPAMINE AGONIST

Drug: Bromocriptine (Cycloset - quick-release formulation for DM)

Mechanism: Activates dopamine D2 receptors in hypothalamus → improves insulin sensitivity by resetting circadian regulation of glucose metabolism; reduces postprandial glucose.

Adverse effects: Nausea, orthostatic hypotension, somnolence, rhinitis.

Advantage: Weight neutral; some cardiovascular protection signal (Cycloset Safety Trial).

CLASS 12: BILE ACID SEQUESTRANTS

Drug: Colesevelam (Welchol)

Mechanism for DM: Not fully understood; may reduce hepatic glucose production by altering bile acid signaling in the gut and liver via FXR pathway.

Adverse effects: Constipation, bloating, hypertriglyceridemia.

Note: Also lowers LDL cholesterol - dual benefit in DM patients with dyslipidemia.

Summary Comparison Table

Class	Drugs	Mechanism	Hypoglycemia	Weight	CV/Renal Benefit
Insulin	Lispro, Aspart, Regular, NPH, Glargine, Degludec	Direct insulin replacement	Yes (major risk)	Gain	Yes (essential)
Biguanide	Metformin	↓ Hepatic gluconeogenesis	No	Neutral/Loss	Yes (UKPDS)
Sulfonylureas	Glipizide, Glyburide, Glimepiride	↑ Insulin secretion (SUR-1)	Yes	Gain	No
Meglitinides	Repaglinide, Nateglinide	↑ Insulin secretion (SUR-1)	Low risk	Gain	No
TZDs	Pioglitazone, Rosiglitazone	PPAR-γ agonist → insulin sensitivity	No	Gain	Pioglitazone (modest)
DPP-4 inhibitors	Sitagliptin, Linagliptin, Alogliptin	Prolong endogenous GLP-1/GIP	Very low	Neutral	Neutral
GLP-1 agonists	Liraglutide, Semaglutide, Dulaglutide	GLP-1 receptor activation	Low	Loss	Yes (CV mortality)
SGLT-2 inhibitors	Empagliflozin, Canagliflozin, Dapagliflozin	Glucosuria via SGLT-2 block	No	Loss	Yes (HF, CKD, CV)
α-Glucosidase inhibitors	Acarbose, Miglitol	Delay CHO absorption	No	Neutral	No
Amylin analog	Pramlintide	Amylin receptor → ↓ glucagon, gastric emptying	With insulin	Loss	No
Dopamine agonist	Bromocriptine	D2 receptor → insulin sensitivity	No	Neutral	Possible
Bile acid sequestrant	Colesevelam	↓ Hepatic glucose + ↓ LDL	No	Neutral	Lipid benefit

Treatment Algorithm for Type 2 DM (ADA Guidelines)

Start: Metformin + lifestyle modification at diagnosis
If A1C not at goal with metformin AND...
- Established ASCVD or high CV risk → add GLP-1 RA (liraglutide, semaglutide, dulaglutide) or SGLT-2i (empagliflozin, canagliflozin)
- Heart failure (HFrEF) → add SGLT-2i (empagliflozin, dapagliflozin)
- CKD → add SGLT-2i or GLP-1 RA
- Need to minimize hypoglycemia → DPP-4i, GLP-1 RA, or SGLT-2i
- Need to minimize weight → GLP-1 RA or SGLT-2i
- Cost is a concern → Sulfonylureas (generic, inexpensive)
Advanced disease with inadequate control: Add/intensify insulin therapy

Standard vs. Intensive Insulin Therapy (Landmark DCCT Trial)

Intensive therapy (A1C ≤7%): Significant reduction in retinopathy (76%), nephropathy (50%), neuropathy (60%)
Trade-off: 3x higher rate of severe hypoglycemia
NOT recommended for: elderly patients, hypoglycemia unawareness, longstanding diabetes with advanced complications

Lippincott Illustrated Reviews: Pharmacology, Ch. 24 | Katzung Basic & Clinical Pharmacology 16e, Ch. 41

Lab diagnosis of Cholera vibrio

Reading File

Finding Sources

Reading File

Loading Image

Reading File

I now have comprehensive textbook content from Jawetz, Park's, and Medical Microbiology. Let me now compile the full detailed answer.

Laboratory Diagnosis of Cholera (Vibrio cholerae)

Sources: Jawetz Melnick & Adelberg's Medical Microbiology 28e; Medical Microbiology 9e; Park's Textbook of Preventive & Social Medicine; Quick Compendium of Clinical Pathology 5e

1. The Organism at a Glance

Feature	Detail
Morphology	Comma-shaped / curved Gram-negative rod, 1 × 2-4 µm
Motility	Single polar flagellum; highly motile
Metabolism	Fermentative, facultative anaerobe; oxidase positive
pH preference	Grows optimally at alkaline pH 8.5-9.5; rapidly killed by acid
Salt requirement	V. cholerae O1 can grow WITHOUT additional NaCl (unlike other vibrios)
Key serogroups causing epidemic cholera	O1 and O139 only
O1 serotypes	Ogawa, Inaba, Hikojima
O1 biotypes	Classical and El Tor (El Tor is VP positive, hemolysin-producing, polymyxin B resistant)
O139 features	Encapsulated (unlike O1); produces cholera toxin; causes cholera-like epidemics

2. Specimen Collection

(a) Stool (Primary Specimen)

Collect early in the course of illness - vibrio numbers are highest at onset and fall rapidly
Collect before antibiotic therapy
Methods:
- Rubber catheter (best): Sterilized No. 26-28 soft rubber catheter introduced 4-5 cm into rectum; specimen collected directly into transport medium
- Rectal swab: Cotton-tipped swab soaked in liquid stool or introduced into rectum, immediately dipped in holding medium
- Liquid stool in a sterile container is also acceptable

(b) Transport Media (Critical - especially for delayed processing)

Medium	Notes
Cary-Blair medium	Best for delayed transport; keeps organisms viable for days; refrigerate
Alkaline Peptone Water (APW), pH 8.5	Doubles as enrichment; standard holding medium
Venkatraman-Ramakrishnan (VR) medium	Used for larger stool specimens; classic Indian field medium
No transport medium available	Soak rectal swab in stool, seal in sterile plastic bag; must reach lab within hours

Specimens must be inoculated onto agar within 2-4 hours of collection for optimal recovery.

3. Direct Microscopic Examination

Dark-Field / Phase-Contrast Microscopy

Fresh stool or enrichment broth (after 5-6 hours incubation in APW) examined under dark-field illumination
Positive finding: "Shooting star motility" - vibrios dart across the dark field like shooting stars in a dark sky
Can diagnose ~80% of cases within minutes during epidemics
Immobilization test (presumptive confirmation): Add a drop of polyvalent anti-O1 antiserum to a wet preparation:
- Motility ceases → presumptively V. cholerae O1
- No change in motility → organism is NOT V. cholerae O1
Limitation: not distinctive on routine smears; becomes negative as disease progresses; not routinely recommended outside epidemic settings

Gram Stain

Curved to comma-shaped Gram-negative rods (Figure above - Jawetz)
On prolonged culture may appear as straight rods

Gram stain of V. cholerae showing the characteristic curved (comma-shaped) morphology. (Jawetz Medical Microbiology)

4. Culture Methods

Step 1 - Enrichment (Selective enrichment broth)

Medium	Details
Alkaline Peptone Water (APW) pH 8.5, with 1% NaCl	Inoculate 0.5-1.0 ml stool; incubate 6-8 h at 37°C; V. cholerae grows on surface pellicle
Taurocholate Peptone Broth (TCP) pH 8.0-9.0	Alternative enrichment; subculture after 6-8 h
Peptone Water Tellurite (PWT)	Used in some labs; incubate 4-6 h at 37°C then subculture

After enrichment, loop from the surface (vibrios grow as a pellicle at the top) and subculture onto selective agar.

Step 2 - Selective Agar Plates

TCBS Agar (Thiosulfate-Citrate-Bile Salts-Sucrose) - Primary Selective Medium

Feature	V. cholerae on TCBS
Colony color	Yellow (ferments sucrose)
Background	Dark green agar
Colony appearance	Glistening, 2-3 mm, yellow colonies surrounded by diffuse yellowing of indicator
Incubation	18-24 h at 37°C
Selectivity	Inhibits most enteric bacteria (coliforms, Salmonella, Shigella)

Comparison: V. parahaemolyticus and V. vulnificus produce green colonies (do not ferment sucrose).

Bile Salt Agar (BSA), pH 8.6

V. cholerae: translucent, moist, raised, smooth, easily emulsifiable colonies ~1 mm diameter
Plates screened under oblique light illumination for typical vibrio colonies
Used when TCBS not available

Other media that support growth:

Blood agar - grows well (smooth, round, opaque, granular in transmitted light)
MacConkey agar - grows (some strains may be inhibited)
Note: Alkaline pH strongly favors vibrio growth over normal enteric flora

5. Biochemical Identification

Test	V. cholerae result
Oxidase test	Positive (key preliminary test - distinguishes vibrios from Enterobacteriaceae)
Gram stain	Curved Gram-negative rod
Sucrose fermentation	Positive (yellow on TCBS)
Mannose fermentation	Positive
Arabinose fermentation	Negative
String test (0.5% sodium deoxycholate)	Positive - forms mucoid string (cell lysis releases DNA)
TSI (Triple Sugar Iron) agar	Acid/Acid (yellow slant/yellow butt - sucrose fermentation); no H₂S
Indole test	Positive
Voges-Proskauer (VP) test	Positive (El Tor biotype); Negative (Classical biotype)
Growth at 0% NaCl	Positive (unlike other halophilic vibrios)
Polymyxin B sensitivity	Resistant (El Tor); Sensitive (Classical)
Hemolysin production	El Tor: positive; Classical: variable

The oxidase test is the single most important preliminary step - distinguishes Vibrio from Enterobacteriaceae (all of which are oxidase negative).

6. Serological Identification (Serogrouping/Serotyping)

Slide Agglutination Test

Pick a suspected colony from BSA/TCBS
Make a homogeneous suspension in 0.85% sterile saline on a glass slide
Add one drop of polyvalent anti-cholera O1 diagnostic serum
Positive agglutination = V. cholerae O1
If positive with polyvalent serum → repeat with monovalent Inaba serum and Ogawa serum:
- Agglutinates with Inaba antiserum only → Inaba serotype
- Agglutinates with Ogawa antiserum only → Ogawa serotype
- Agglutinates with both → Hikojima serotype (rare)
If no agglutination with O1 antiserum → test with O139 antiserum
Colonies that don't agglutinate with either O1 or O139 sera → test oxidase + string tests → classify as non-O1/non-O139 V. cholerae

Antigenic Structure

Antigen	Details
H antigen	Single heat-labile flagellar antigen; shared by all vibrios; not protective
O antigen (LPS)	Determines serogroup; >200 serogroups; O1 and O139 cause epidemic cholera
O1 antigen	Not capsulated; further divided into Inaba, Ogawa, Hikojima
O139 capsular polysaccharide	Encapsulated; does not carry O1 LPS genes; also produces cholera toxin

7. Biotyping (Differentiating Classical vs. El Tor)

Test	Classical	El Tor
Voges-Proskauer	Negative	Positive
Hemolysin of sheep RBCs	Negative	Positive (thermostable hemolysin)
Polymyxin B (50 IU disc)	Sensitive (inhibited)	Resistant
Phage IV sensitivity	Sensitive	Resistant
Agglutination of chicken RBCs	Negative	Positive
El Tor disease	Milder (75% asymptomatic)	Pandemic strain since 7th pandemic

8. Rapid/Newer Diagnostic Methods

Method	Notes
Immunochromatographic dipstick test	Rapid field test; detects O1 and O139 LPS antigens in stool; sensitive and specific; results in 10-15 min; used in epidemic settings
Immunofluorescence	Direct detection using fluorescent-labeled antibodies against O1/O139
Latex agglutination	Rapid; detects V. cholerae O1 antigens
ELISA (cholera toxin detection)	Detects cholera toxin; variable analytical performance
Multiplex PCR / NAAT (nucleic acid amplification)	Test of choice per Medical Microbiology 9e; detects ctxA (cholera toxin gene), tcpA (toxin-coregulated pilus), and ompW genes; can simultaneously detect many enteric pathogens; highly sensitive and specific
MALDI-TOF MS	Rapid and reproducibly accurate identification from culture; promising newer methodology
Widal-like serology (vibriocidal antibodies)	Vibriocidal antibody titer ≥1:20 in serum = associated with protection; used in seroepidemiological surveys, not acute diagnosis

9. Stepwise Laboratory Diagnosis Summary

PATIENT STOOL (early in illness, before antibiotics)
         │
         ▼
TRANSPORT MEDIUM: Cary-Blair / Alkaline Peptone Water
         │
         ▼
DIRECT EXAMINATION
  • Wet mount: "Shooting star" motility on dark-field
  • Immobilization with polyvalent O1 antiserum → presumptive
  • Gram stain: curved Gram-negative rods
         │
         ▼
ENRICHMENT: Alkaline Peptone Water (APW), pH 8.5 - 6-8 h at 37°C
         │
         ▼
SUBCULTURE ON SELECTIVE MEDIA
  • TCBS agar → YELLOW colonies (sucrose fermenter)
  • Bile Salt Agar → translucent, moist, smooth colonies
         │
         ▼
PRELIMINARY IDENTIFICATION
  • Oxidase test → POSITIVE ✓ (key step)
  • String test → POSITIVE ✓
  • Gram stain and motility (hanging drop)
         │
         ▼
SEROLOGICAL CONFIRMATION
  • Slide agglutination with polyvalent O1 antiserum
  • If positive → Inaba + Ogawa monovalent sera → serotyping
  • If O1 negative → test with O139 antiserum
         │
         ▼
BIOCHEMICAL CONFIRMATION + BIOTYPING
  • Fermentation: sucrose+, mannose+, arabinose-
  • VP test, polymyxin B sensitivity (El Tor vs Classical)
         │
         ▼
FINAL REPORT: V. cholerae O1 (serotype Ogawa/Inaba), El Tor biotype
              OR V. cholerae O139 Bengal
              OR non-O1/non-O139 V. cholerae

10. Key Colony/Media Characteristics at a Glance

Medium	V. cholerae appearance	Significance
TCBS agar	Yellow, glistening, 2-3 mm	Primary selective medium; sucrose fermentation
Blood agar	Smooth, round, opaque; may show beta-hemolysis (El Tor)	Non-selective; all vibrios grow
MacConkey agar	Small, pale (non-lactose fermenter)	Non-selective; some strains inhibited
Bile Salt Agar	Translucent, moist, 1 mm, easily emulsifiable	Classic medium; viewed under oblique light
TCBS - V. parahaemolyticus	Green (no sucrose fermentation)	Important differential

11. Special Points

Notification: Cholera is a notifiable disease - must be reported to WHO within 24 hours under International Health Regulations
Non-O1/non-O139 strains: cause self-limited gastroenteritis; do NOT produce cholera toxin; do not cause epidemic cholera
O139 Bengal: emerged in 1992; encapsulated; produces cholera toxin; can affect individuals immune to O1; requires specific O139 antiserum for identification
False-negative cultures: V. cholerae can enter a viable but non-culturable (VBNC) state in the aquatic environment between outbreaks - PCR detects these when culture fails
Specimen from contacts/water: 1-3 L water samples filter-concentrated; or added to peptone water (1:9) for enrichment

Jawetz Melnick & Adelberg's Medical Microbiology 28e, Ch. 17 | Medical Microbiology 9e | Park's Textbook of Preventive & Social Medicine, Ch. Cholera | Quick Compendium of Clinical Pathology 5e

This is a shared conversation. Sign in to Orris to start your own chat.